DeepQure Revolutionizes Hypertension Treatment with Innovative Technology in Global Trials

DeepQure's Breakthrough in Hypertension Treatment

DeepQure Inc., a cutting-edge medical device startup based in South Korea, is setting new standards in the fight against resistant hypertension using its innovative renal denervation (RDN) technology known as HyperQure™. This next-generation device stands out from traditional catheter-based systems by adopting a unique extravascular laparoscopic approach, which aims to provide more effective and targeted sympathetic nerve ablation. The technology significantly minimizes the limitations associated with existing treatments and promises to enhance patient outcomes.

Progress in Global Clinical Trials

The company is progressing rapidly with clinical trials in both South Korea and the United States. In South Korea, DeepQure has reported successful outcomes in seven patients who underwent the procedure, demonstrating remarkable reductions in blood pressure without encountering any adverse effects either during or after the operation. The company is on track to complete patient enrollment for its Korean clinical trial by the end of the first quarter of 2025.

Meanwhile, the U.S. clinical trial has also shown promise, with the first procedure completed on January 17, 2025, at the University of California, Irvine (UC Irvine), led by Dr. Pengbo Jiang. The results yielded significant blood pressure reductions one month post-operation without complications. The next patient is scheduled for treatment in March, while approvals for additional clinical sites have been secured from prestigious institutions, including Mayo Clinic and Stanford University.

The U.S. clinical study is designed to include six leading university hospitals, with the ambition to enroll 15 patients by mid-2025, eventually aiming to initiate a pivotal study by the end of the year to further validate the safety and efficacy of HyperQure™.

Expansion into Atrial Fibrillation Treatment

Not stopping at hypertension, DeepQure is broadening its horizons by applying its RDN technology to treat atrial fibrillation (Afib), one of the most prevalent cardiac arrhythmias. An application for initiating clinical trials for Afib treatment has been submitted to South Korea’s Ministry of Food and Drug Safety (MFDS). Currently, the standard treatment for Afib involves Pulmonary Vein Isolation (PVI), which suffers from a substantial recurrence rate of approximately 30-50%. DeepQure’s RDN technology is expected to enhance PVI outcomes by mitigating this recurrence, offering a new avenue for patients where previous drug therapy options have largely fallen short.

Pioneering the Future of Cardiovascular Care

With its innovative technology and growing clinical momentum, DeepQure is positioning itself at the forefront of the medical device industry. The global RDN market, valued at $1.3 billion in 2024, is anticipated to soar to $10.3 billion by 2031, showcasing a compound annual growth rate of 34.4%. As DeepQure advances its clinical initiatives and navigates regulatory landscapes, the company is dedicated to setting new standards in cardiovascular care, ultimately bringing transformative solutions to patients across the globe.

DeepQure is not merely advancing technology; it is above all committed to reshaping the therapeutic landscape for resistant hypertension and cardiac arrhythmias. As they forge ahead, the potential for life-enhancing solutions becomes increasingly tangible for patients and the medical community alike.